Smartphone-integrated consumer baby monitors that measure vital signs are popular among parents but are not regulated by the US Food and Drug Administration (FDA). [1] [2] [3] [4] This study measured the accuracy of pulse oximetry-based consumer baby monitors using an FDA-cleared oximeter as a reference.
Methods | We purchased the only 2 currently marketed smartphone-integrated consumer baby monitors that use pulse oximetry, the Owlet Smart Sock 2 (consumer monitor A) and Baby Vida (consumer monitor B). We enrolled infants aged 0 to 6 months hospitalized in general pediatrics and cardiology wards at the Children's Hospital of Philadelphia from July through December 2017. Infants were excluded if born before 34 weeks' gestation, critically ill, anemic (hemoglobin <10 g/dL), febrile (≥38.0°C), hypothermic (<36.0°C), hypotensive (systolic blood pressure <60 mm Hg if 0-28 days old or <70 mm Hg if 29 days-6 months old), or had compromised perfusion. Written informed consent was obtained from infants' parents. The Children's Hospital of Philadelphia's institutional review board approved the study.
On 1 foot, infants were monitored using a Masimo Radical-7 with 16-second averaging (reference monitor). Each consumer monitor was applied to the other foot of all infants in a random sequence for 60 minutes while asleep or awake and calm.
We identified "stable" paired reference monitorconsumer monitor points that met criteria: (1) for the reference monitor, during the prior 30 seconds, oxygen saturation (SpO 2 ) varied by 1 percentage point or less in either direction for SpO 2 comparisons or pulse rate varied by 5 beats/min or less in either direction for pulse rate comparisons and (2) for the consumer monitor, during the prior 30 seconds, no dropout (defined as failure to display a value). To minimize ascertainment bias, we randomly selected up to 10 stable points per patient for analysis. We generated scatterplots and calculated sensitivity and specificity for hypoxemia (SpO 2 <91%) 5 and bradycardia (pulse rate <90 beats/min), 6 accounting for , the most common diagnoses were bronchiolitis (27%), apnea or brief resolved unexplained event (10%), hypoplastic left heart syndrome (10%), and double outlet right ventricle (10%). We recorded 2466 stable SpO 2 and 1801 stable pulse rate points. Using monitor A, 5 patients had fewer than 10 stable SpO 2 points and 10 patients had fewer than 10 stable pulse rate points. Using monitor B, 3 patients had fewer than 10 stable pulse rate points. Figure 1 and Figure 2 display scatterplots for SpO 2 and pulse rate. During testing of monitor A, 12 patients experienced hypoxemia according to the reference monitor and all 12 had at least 1 simultaneous hypoxemia reading on monitor A, although 5 of the 12 each had at least 1 stable normoxemic reading on monitor A during hypoxemia. During testing of monitor B, 14 patients experienced hypoxemia according to the reference monitor, but none had simultaneous hypoxemia readings on monitor B. All SpO 2 readings on monitor B were in the normal range. Monitor A had 0 instances of falsely displaying bradycardic pulse rates when the reference monitor rate was normal. However, in 14 patients, monitor B falsely displayed bradycardic pulse rates when the reference monitor rate was normal.
For monitor A, the sensitivity and specificity for hypoxemia were 88.8% and 85.7%, respectively, and for bradycardia were 0.0% and 100.0%, respectively.
For monitor B, the sensitivity and specificity for hypoxemia were 0.0% and 100.0%, respectively, and for bradycardia were 0.0% and 82.3%, respectively. Discussion | Accuracy testing of 2 SpO 2 -based baby monitors that are not FDA-regulated revealed concerning findings. Monitor A detected hypoxemia but performed inconsistently. Monitor B never detected hypoxemia and also displayed falsely low pulse rates. Beyond their accuracy, other concerns about consumer monitor use include the lack of medical indications for monitoring infants at home, the absence of FDA oversight, and the potential for unintended consequences. 1 The main study limitation is the use of a pulse oximeter as the reference standard; arterial blood gas measurements would be preferred but limit feasibility.
As more neonate and infant vital sign monitors emerge in this largely unregulated market, physicians and parents should exercise caution incorporating data from these monitors into medical decisions. To minimize ascertainment bias, we randomly selected up to 10 stable points per patient per consumer monitor for analysis. The dotted lines indicate cut points for bradycardia (pulse rate <90 beats/min). The solid line represents perfect agreement between the consumer monitor and reference monitor. Jitter (spherical random noise) added to prevent data points from overprinting using Stata graph option "jitter(1)."
A, Plot displays 235 randomly selected observations from 28 patients. Bradycardia prevalence was 0.8%; sensitivity, 0.0% (97.5% CI, 0.0%-84.2%); specificity, 100.0% (97.5% CI, 98.4%-100.0%).
B, Plot displays 294 randomly selected observations from 30 patients. Bradycardia prevalence was 0.3%; sensitivity, 0.0% (97.5% CI, 0.0%-97.5%); specificity, 82.3% (97.5% CI, 72.5%-92.0%).
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